UBS Group
BBNX

UBS Group’s Beta Bionics BBNX Stock Holding History

UBS Group’s Portfolio BBNX Stock Details BBNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.24M Buy
623,253
+371,815
+148% +$5.5M ﹤0.01% 3828
2025
Q4 		$7.66M Buy
251,438
+123,533
+97% +$3.3M ﹤0.01% 3580
2025
Q3 		$2.54M Buy
127,905
+31,844
+33% +$560K ﹤0.01% 4733
2025
Q2 		$1.4M Sell
96,061
-28,279
-23% -$400K ﹤0.01% 5149
2025
Q1 		$1.52M Buy
+124,340
New +$2.32M ﹤0.01% 4921

Other funds holding BBNX

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

UBS Group's BBNX Position: Q1 2026 in Review

UBS Group increased its Beta Bionics (BBNX) stake by 148% in Q1 2026, buying an estimated $5.5M and bringing the position to 623,253 shares worth $6.24M. The position accounts for ﹤0.01% of the portfolio, ranked #3828.

UBS Group first reported a position in BBNX in Q1 2025 and has held it in 5 quarters since. The position peaked at $7.66M in Q4 2025. 130 funds tracked by Wall St. Rank hold BBNX as of Q1 2026.

  • UBS Group held 623,253 shares of Beta Bionics worth $6.24M as of Q1 2026.
  • UBS Group bought 371,815 Beta Bionics shares in Q1 2026, an estimated $5.5M.
  • Beta Bionics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #3828 holding.
  • UBS Group first reported a position in Beta Bionics in Q1 2025 and has held it in 5 quarters since.
  • UBS Group's Beta Bionics position peaked at $7.66M in Q4 2025.
  • 130 funds tracked by Wall St. Rank held Beta Bionics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.